Supplementary Figures 1-5 from <i>In Vivo</i> ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma

Supplemental Fig. 1. Combination-resistant and combination tolerant tumors re-activated ERK1/2 before progression. Supplemental Fig. 2. Combination-resistant tumor-derived cell lines progressed through cell cycle during combo treatment. Supplemental Fig 3. CRTs harbored tandem duplication of kinase domain but remained sensitive to ERK1/2 inhibition. Supplemental Fig. 4. Both intermittently and continuously treated tumors reactivated of ERK1/2 in vitro. Supplemental Fig. 5. Pathway analysis identified Plk11 as selective driver of resistance in CRTs.